Host: |
Rabbit |
Applications: |
WB/IF |
Reactivity: |
Human/Rat |
Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Short Description: |
Rabbit monoclonal antibody anti-CR2/CD21 (934-1033) is suitable for use in Western Blot and Immunofluorescence research applications. |
Clonality: |
Monoclonal |
Clone ID: |
S8MR |
Conjugation: |
Unconjugated |
Isotype: |
IgG |
Formulation: |
PBS with 0.05% Proclin300, 0.05% BSA, 50% Glycerol, pH7.3. |
Purification: |
Affinity purification |
Dilution Range: |
WB 1:500-1:1000IF/ICC 1:50-1:200 |
Storage Instruction: |
Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
Gene Symbol: |
CR2 |
Gene ID: |
1380 |
Uniprot ID: |
CR2_HUMAN |
Immunogen Region: |
934-1033 |
Immunogen: |
A synthetic peptide corresponding to a sequence within amino acids 934-1033 of human CR2/CD21 (P20023). |
Immunogen Sequence: |
GAVVTLECEDGYMLEGSPQS QCQSDHQWNPPLAVCRSRSL APVLCGIAAGLILLTFLIVI TLYVISKHRARNYYTDTSQK EAFHLEAREVYSVDPYNPAS |
Tissue Specificity | Mature B-lymphocytes, T-lymphocytes, pharyngeal epithelial cells, astrocytes and follicular dendritic cells of the spleen. |
Function | Receptor for complement C3, for the Epstein-Barr virus on human B-cells and T-cells and for HNRNPU. Participates in B lymphocytes activation. (Microbial infection) Acts as a receptor for Epstein-Barr virus. |
Protein Name | Complement Receptor Type 2Cr2Complement C3d ReceptorEpstein-Barr Virus ReceptorEbv ReceptorCd Antigen Cd21 |
Database Links | Reactome: R-HSA-977606 |
Cellular Localisation | Cell MembraneSingle-Pass Type I Membrane Protein |
Alternative Antibody Names | Anti-Complement Receptor Type 2 antibodyAnti-Cr2 antibodyAnti-Complement C3d Receptor antibodyAnti-Epstein-Barr Virus Receptor antibodyAnti-Ebv Receptor antibodyAnti-Cd Antigen Cd21 antibodyAnti-CR2 antibodyAnti-C3DR antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance